Karyopharm Seeks FDA Approval for Innovative Myelofibrosis Treatment with XPOVIO and Ruxolitinib

Karyopharm's Ambitious Submission for Accelerated Approval

Karyopharm Therapeutics Inc., known for its cutting-edge cancer therapies, recently took a significant step by submitting a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA). This application seeks Accelerated Approval for their innovative treatment combining XPOVIO® (selinexor) and ruxolitinib for patients battling myelofibrosis, a rare blood cancer.

The urgency of this submission is underscored by the profound unmet medical need faced by myelofibrosis patients. According to Reshma Rangwala, M.D., Ph.D., Karyopharm's Chief Medical Officer, the combination treatment aims to provide these patients with a valuable option, given the condition's severity and the lack of effective therapies.

Karyopharm has made clear that they have requested Priority Review for their application, which could expedite the review process to just six months. Their confidence is bolstered by promising results from the Phase 3 SENTRY trial, which indicated rapid, significant, and sustained responses regarding spleen volume reduction among participants. These clinical results reinforce the therapy's potential to improve both survival outcomes and the overall quality of life for patients.

Understanding Myelofibrosis

Myelofibrosis affects around 20,000 people in the United States, leading to severe symptoms such as anemia, fatigue, and splenomegaly (enlarged spleen) due to bone marrow scarring. As the disease progresses, the ability of bone marrow to produce healthy blood cells diminishes, making effective treatment crucial.

Currently, the approved therapies mainly consist of JAK inhibitors like ruxolitinib. However, the introduction of the XPOVIO and ruxolitinib combination represents a hopeful advancement, particularly for patients who have not responded to existing treatments.

Insights into the SENTRY Trial

The SENTRY trial, with the designation XPORT-MF-034 (NCT04562389), is pivotal in evaluating the dosing regimen for the new combination therapy. It involved a randomized setup, with patients receiving either a once-weekly dose of 60 mg of selinexor alongside ruxolitinib or a placebo with ruxolitinib. The primary endpoints included significant spleen volume reduction (≥ 35%) and overall symptom relief over 24 weeks.

These findings were not only presented at prestigious events like the American Society of Clinical Oncology Annual Meeting but were also featured in the Journal of Clinical Oncology, emphasizing the scientific community's interest in Karyopharm's efforts. The highlight was the combination's ability to deliver substantial benefits, as evidenced by the trial's eye-catching results.

Future Prospects and FDA Engagement

After the submission of the sNDA, Karyopharm has been in ongoing discussions with the FDA to ensure clarity on the expectations for Accelerated Approval. Specifically, the FDA will need to validate that a spleen volume reduction of 35% (SVR35) can reasonably predict improved overall survival. Continuing efforts include the collection of long-term data to reinforce these claims and facilitate transition from accelerated to standard approvals.

Karyopharm expresses optimism that the FDA's decision regarding the acceptance of this filing will be revealed by the end of 2026, following a 60-day evaluation period. The company remains committed to constant communication with the FDA to confirm and solidify their evidence plan during this time.

Regulatory Recognitions for Selinexor

Prior to this submission, selinexor had already been given Orphan Drug Designation by the FDA in May 2022, signaling its potential for treating myelofibrosis. Additionally, in October 2022, the European Commission recognized selinexor in the same capacity, and just recently, in July 2023, it received Fast Track Designation from the FDA, signifying a focused effort to address patient needs uniquely with this treatment.

As Karyopharm continues to explore the potential of selinexor across various myeloproliferative diseases, there’s a tangible sense of hope for patients searching for effective treatments. XPOVIO's journey stands as a reminder of the strides being made within cancer therapeutics, showcasing the important steps toward alleviating the hardships faced by myelofibrosis patients.